Blocking a Single Immune Receptor Restores Cellular Cleanup and Reverses Age-Related Decline in Mice

On September 1, 2026, Stanford Medicine researchers detailed a mechanism that drives systemic aging, demonstrating that blocking a single immune receptor in older mice restored their cellular cleanup systems and reversed age-related decline across multiple organs. The findings, which build on research published in the journal Science, show that disabling the EP2 receptor on tissue-resident macrophages allows these cells to resume consuming worn-out neutrophils. By removing this specific blockade, the researchers were able to halt the chronic inflammation that typically degrades the brain, heart, and skeletal muscle as mammals grow older.[1][4]

The body produces roughly 100 billion neutrophils daily to act as frontline responders to bacterial, viral, and fungal threats. Because these white blood cells are highly destructive—capable of releasing toxic substances and forming web-like traps around microbes—they are designed with a strict biological expiration date. They typically survive for only 12 to 24 hours in the bloodstream before they must be cleared away. That disposal task falls to tissue-resident macrophages, which settle in organs during fetal development and act as the immune system's permanent garbage collection crew.[4][5]

As mammals age, this essential cleanup process breaks down. The Stanford team, led by Dr. Jessy Tan and Dr. Katrin Andreasson, found that aging increases the production of prostaglandin E2 (PGE2), one of five types of prostaglandins, which binds to the EP2 receptor on macrophages. This receptor strongly promotes inflammation, and tissue-resident macrophages contain high levels of it. The researchers discovered that unrelenting stimulation by PGE2 effectively shuts down the macrophages' ability to engulf and digest dying cells, leaving the immune system's front-line responders exhausted and unable to perform their basic maintenance duties.[1][4][6]

Left uncleared, the expired neutrophils enter a toxic, senescent state rather than dying off cleanly. "Senescent neutrophils are killing our tissues," Andreasson noted in the study's release. These "zombie" cells accumulate in the bloodstream and major organs, where they leak inflammatory chemicals that damage surrounding healthy tissue and accelerate the physical aging of the environment around them. This localized damage quickly cascades into systemic inflammation, placing additional strain on an already weakened immune system and driving the physical frailty associated with old age.[1][5][6]

To test whether this decline could be reversed, the researchers administered an experimental EP2-blocking drug to 22-month-old mice—an age roughly equivalent to late adulthood in humans—for a period of two months. In a parallel experiment, they also engineered a separate group of mice where the EP2 gene could be selectively deleted in tissue-resident macrophages at 4 to 6 months of age. Both approaches were designed to isolate the effect of the EP2 receptor without disrupting the broader immune system or other beneficial prostaglandin pathways.[4][6]

The targeted intervention halted chronic inflammation and preserved functional youthfulness across a vast network of organs. In the older mice treated with the EP2 inhibitor, both total and senescent neutrophil counts returned to youthful levels. The mice exhibited preserved speed, balance, and grip strength, and they navigated memory mazes almost as effectively as younger mice. By simply restoring the macrophage cleanup mechanism, the researchers prevented the excessive fat accumulation, heart trouble, and cognitive decline that typically plague mice in their final months of life.[1][4][6]

The metabolic improvements were particularly stark in the liver, which Andreasson described as "the central organ determining the body's metabolic rate." The research team tracked 71 specific blood proteins that typically alter in normal 23- to 25-month-old mice. Remarkably, 59 of those proteins remained at youthful levels in the animals lacking the EP2 receptor. The liver is one of the body's most macrophage-enriched organs, and clearing the senescent neutrophils from its tissues allowed it to maintain youthful blood chemistry, detoxification, and nutrient processing.[4][6]

While the experimental drug was tested in mice, the researchers confirmed the same pathological cascade operates in human tissue. By analyzing comprehensive databases of human hepatic cells, the team observed the identical age-related neutrophil buildup, widespread cellular senescence, and heightened macrophage EP2 receptor activity in older and diseased human livers. According to Andreasson, this marked the first time these specific immune-breakdown changes had been directly observed in human cells, validating the EP2 receptor as a highly relevant target for human longevity and disease prevention.[1][5][6]

The immediate challenge for clinical translation is developing a highly selective pharmaceutical that targets the EP2 receptor directly without disrupting broader hormone systems. Current nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin reduce inflammation by blocking PGE2 production upstream, which clumsily shuts down multiple beneficial prostaglandins and can cause long-term side effects like ulcers or kidney stress. For readers, this means that simply taking more over-the-counter painkillers will not replicate these anti-aging effects and carries significant risks. "We need to develop a safe drug," Andreasson stated, emphasizing that the goal is to create a precise shield for the EP2 receptor that leaves the body's helpful inflammatory pathways completely intact.[1][4][5]